Physician profile
Rubin Simon
NPI 1275776205
$3,694.96
in general payments reported to CMS, 2019-2025
28 companies · $28.32 in 2025
The $28.32 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $830 · 2021: $1,020 · 2022: $434 · 2023: $867 · 2024: $94.15 · 2025: $28.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $849.65 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $349.43 | 2019-2024 | Lifevest |
| Vifor Pharma, INC. | $321.89 | 2020-2024 | Zemaira, Veltassa |
| Inari Medical, INC. | $269.55 | 2020-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Aurinia Pharma U.S., INC. | $249.03 | 2023 | Lupkynis |
| Paratek Pharmaceuticals, INC. | $179.81 | 2020-2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.05 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $144.25 | 2020-2023 | Lokelma, Imfinzi, Brilinta |
| Dexcom, INC. | $141.36 | 2021-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $140.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $127.19 | 2020-2024 | |
| Pfizer INC. | $93.05 | 2019-2022 | |
| Shionogi INC | $70.94 | 2021-2025 | Fetroja |
| Novo Nordisk INC | $66.22 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.46 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $62.20 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.07 | 2020-2021 | |
| Melinta Therapeutics, LLC | $51.05 | 2019-2020 | |
| Allergan, INC. | $44.59 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $35.64 | 2022 | |
| Portola Pharmaceuticals, LLC | $33.54 | 2020 | |
| Smith+Nephew, INC. | $29.70 | 2021 | |
| Abbvie INC. | $29.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.84 | 2022 | |
| Biogen, INC. | $24.28 | 2021 | |
| Astellas Pharma US INC | $21.31 | 2022 | |
| Fisher & Paykel Healthcare INC | $17.83 | 2023 | Fisher & Paykel Healthcare |
| Chiesi USA, INC. | $16.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubin Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.